The treatment involves delivering millions of tiny beads containing radioactive yttrium 90 into the hepatic arteries.
Researchers from the University of Maryland, Greenebaum Cancer Center, Baltimore, USA, reported on trials involving 45 patients.
During the trials, doctors changed the approach to delivery, the conference in San Francisco, California, USA, was told. Instead of using a single dose, doctors switched to treating the right lobe of the liver first and then the left lobe up to 4 weeks later.
Doctors said the "most dramatic" improvements were seen in patients with gastrointestinal carcinoid tumors in neuroendocrine cells. Tumors disappeared in all 3 of these patients.
|TheraSphere embolizes tumors with yttrium 90 beads.|
|American Society of Clinical Oncologists |
7 patients had colorectal tumors, and 5 of these were doing well 6 months after treatment, according to Professor David Van Echo.
Professor Van Echo said, "Our experience thus far indicates that the procedure does have benefit for the patient, and we have a better understanding of who's most likely to benefit."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com